Recent 8-K filings for HTCR
Highest-materiality recent filing
HeartCore Q3 revenue $17.9M (+281% YoY), net income $10.8M vs loss a year ago
- Q3 revenue $17.9M (+281% YoY); net income $10.8M ($0.53 diluted EPS) vs net loss of $2.5M a year ago.
- Gross profit surged 1,640% to $14.4M; operating expenses fell to $2.3M from $2.6M.
-
HeartCore regains Nasdaq minimum bid price compliance, listing continues
Received Nasdaq notice on April 20, 2026 that it regained compliance with the $1.00 minimum bid price requirement.
-
HeartCore Enterprises announces 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split ratio set at 1-for-20; effective April 2, 2026 at 4:00 p.m. ET.
-
HeartCore FY2025 rev $9.0M (-60% YoY); net income $5.5M on gain from divestiture
Revenue $9.0M vs $22.7M YoY; prior year included $13M warrant revenue from a large Go IPO deal.
-
Revenue expected $8.5M-$9.5M, down YoY due to divestiture of HeartCore Japan; prior year net loss of $5.2M.
-
HeartCore Q3 revenue falls to $3M, net income $0.4M after divesting software unit
Q3 2025 revenue $3.0M vs $16.2M prior year; prior year included $13M warrant revenue from large Go IPO deal.
-
HeartCore clarifies post-sale equity over $5M; shifts strategy to Go IPO consulting
Sale of HeartCore Japan closed Oct 31 for ¥1.8B (~$12M), with deferred consideration of ¥387M at 6.65% interest due Oct 2028.
-
HeartCore sells software subsidiary for ~$12M; shifts to Go IPO consulting
Sold HeartCore Japan to Volaris Group for ¥1.8B (~$12M) in all-cash; closed Oct 31, 2025.
-
One-time payment of $0.13/share classified as a distribution for U.S. federal tax purposes, correcting earlier dividend statement.
-
HeartCore declares $0.13/share one-time dividend, ~17.8% of stock price, payable Nov 17
One-time dividend of $0.13 per share authorized by Board on October 19, 2025.
-
HeartCore announces Go IPO client rYojbaba begins Nasdaq trading; warrants valued at ~$1.35M
rYojbaba (RYOJ) commenced trading on Nasdaq Capital Market on August 18, 2025.
-
Nasdaq granted extension until September 30, 2025 to regain compliance with $2,500,000 minimum stockholders' equity requirement.
-
Equity Purchase Agreement with Crom for up to $25M in common stock (ELOC); $250K commitment fee in shares.
-
HeartCore secures up to $27M financing: $25M equity line + $2M convertible preferred from Crom Fund
Equity Purchase Agreement: HeartCore may sell up to $25M of common stock to Crom over 24 months at a discount of 50% of average daily trading volume.
-
HeartCore partners with Silver Egg to integrate AI recommend engine into CMS by Aug 2025
OEM agreement signed June 23, 2025, with Silver Egg for its 'Aigent Recommender' AI recommendation service.
-
HeartCore signs 15th Go IPO consulting contract with tmsuk; $500k fee plus 3% warrant
Cash fee of $500,000 payable in three installments: $200k at signing, $150k at 3 months, $150k at 6 months.
-
Received Nasdaq Staff notice on May 24, 2025 for non-compliance with $2.5M minimum stockholders' equity requirement (Rule 5550(b)).
-
HeartCore Q1 revenue falls 28% to $3.6M; net loss widens to $3.1M
Revenue of $3.6M down from $5.0M YoY; on-premise software, Sigmaways, and Go IPO all declined.
-
HeartCore receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Received Nasdaq written notice on May 6, 2025 for failure to meet $1.00 minimum bid price requirement.
-
HeartCore reports 2024 revenue up 39% to $30.4M; net loss attributable improves
FY2024 revenue $30.4M (+39% YoY); gross profit $17.8M (+121% YoY).
-
HeartCore loses controlled company status; forms compensation and nominating committees
Sumitaka Yamamoto's voting power fell below 50% after ATM sales, triggering loss of controlled company status.
-
HeartCore Q3 revenue $17.9M (+281% YoY), net income $10.8M vs loss a year ago
Q3 revenue $17.9M (+281% YoY); net income $10.8M ($0.53 diluted EPS) vs net loss of $2.5M a year ago.
-
HeartCore regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq notice on Nov 5, 2024 confirming compliance with $1.00 minimum bid price requirement.
-
HeartCore corrects press release: sales growth projection lowered from 115% to 15%
HeartCore expanded its CMS platform to a SaaS delivery model, leveraging AWS infrastructure.
-
HeartCore to appeal Nasdaq delisting; preliminary Q3 revenue up 263-305% YoY
Received Nasdaq notice on Oct 22, 2024 for non-compliance with $1 minimum bid price; trading suspended Oct 31 if no appeal.
-
HeartCore receives Nasdaq delisting notice for bid price non-compliance; intends to appeal
Received Oct 22, 2024 Nasdaq notice for failure to maintain $1.00 minimum bid price for continued listing.
-
HeartCore preliminary Q3 2024 revenue $17-19M vs $4.7M YoY; net income $9-11M vs loss of $2.5M
Revenue expected $17-19M, up 263-305% YoY; net income $9-11M vs $2.5M loss in Q3 2023.
-
SBC Medical Group begins trading on Nasdaq; HeartCore guides Q3 rev $19-23M, net profit $4-8M
Go IPO client SBC Medical Group commenced trading on Nasdaq Global Market under symbol 'SBC'.
-
HeartCore Q2 revenue down 20% to $4.1M, net loss widens to $2.2M; dividend authorized
Net loss of $2.2M ($0.09 diluted EPS) vs net loss of $1.0M ($0.04) in Q2 2023.
-
HeartCore declares $0.02 per share quarterly dividend, second payment
Second dividend of $0.02 per share, aggregate $417,283; record date Aug 19, payable Aug 26, 2024.
-
HeartCore Q1 revenue $5.0M (down 43% YoY); net loss $1.5M vs prior year net income $1.8M
Revenue $5.0M vs $8.7M YoY; decline due to lower Go IPO consulting from two clients listing on Nasdaq last year.
-
HeartCore updates on $9M warrant sale; cash received, revenue deferred until client IPO in Fall 2024
Gross $9M from sale of Go IPO warrant to Japanese financial institution; $5M received Q1 2024, $4M in April.
-
HeartCore gets Nasdaq extension to Oct 21, 2024 to cure bid price deficiency
Received Bid Price Notice Oct 26, 2023 for non-compliance with $1.00 minimum bid price.
-
HeartCore signs 14th Go IPO contract with Koei Shoji; $500K fees plus 3% warrant
Signed consulting agreement with Koei Shoji Co., Ltd. to assist in U.S. listing on Nasdaq or NYSE.
-
Revenue $21.8M (+148% YoY); gross profit $8.1M (+140.7%); net loss $4.9M ($0.21/diluted share).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material